2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual

Partnering Events:

TechConnect Summit
Clean Technology 2008

Aphios Corporation

T. Castor
Aphios Corporation, US

pharmaceuticals, biotech

Lack of sufficient oral bioavailability hinders development of potential anticancer drugs. By enhancing the oral bioavailability of such compounds, therapeutically beneficial products could be developed, especially where long-term exposure is needed for maximum therapeutic effect. If successful, these techniques can be applied to a number of existing drugs as well as to several potential drug candidates of interest to the pharmaceutical industry and the National Cancer Institute. Oral formulation will reduce or eliminate the need for protracted intravenous drug delivery. This will not only benefit patients in terms of convenience, but will also reduce the overall costs of treatment by reducing ohospitalization and visits to clinics, and improve patients’ quality-of-life. Based on preliminary data and scientific rationalization, we hypothesized and then demonstrated that encapsulated anticancer drug nanoparticles in biodegradable polymer nanospheres will allow transport to the stomach and enhance bioavailability. We also hypothesized and demonstrated that both drug nanoparticles and the encapsulation of these particles in biodegradable polymer nanospheres can be formed utilizing supercritical fluid technologies. This approach has averted the use of conventional organic phase techniques that utilize a number of processing steps, large quantities of organic solvents, and are very time consuming, costly and inefficient.

Nanotech 2008 Conference Program Abstract